About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Thompson Davis & Co., Inc. Portfolio

Follow Thompson Davis & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Davis & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on Thompson Davis & Co., Inc. with notifications on news.